Literature DB >> 17253596

Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.

G J Gordon1, M Mani, L Mukhopadhyay, L Dong, H R Edenfield, J N Glickman, B Y Yeap, D J Sugarbaker, R Bueno.   

Abstract

Inhibitor of apoptosis proteins (IAPs) comprise a family of structurally similar proteins, five of which are widely studied in the context of cancer: IAP-1/MIHC/cIAP2, IAP-2/MIHB/cIAP1, livin/ML-IAP/KIAP, survivin, and XIAP/MIHA/hILP. IAPs are overexpressed by most neoplasms, promote tumour cell survival after a wide variety of apoptotic stimuli, and frequently have gene and/or protein expression patterns associated with a relatively poor prognosis. However, many IAPs are also expressed by normal tissues, can facilitate apoptotic cell death, and have expression patterns associated with a relatively favourable prognosis in some cases. The result is that the precise role(s) of IAPs in human tumours is not exactly known. It has been previously reported that IAP-1 is overexpressed in malignant pleural mesothelioma (MPM) and is responsible for a large degree of the resistance of cultured MPM cells to cisplatin. Given the high homology of IAP family members, it is likely that other IAPs will be important in MPM. In the present study, the gene and protein expression patterns of IAP-1, IAP-2, survivin, livin, and XIAP have been determined in MPM cell lines (n=9) and a large number of MPM tumours using high-density oligonucleotide microarrays (n=40) and an MPM tissue array (n=66). Human tumours were linked to clinical data and it was found that IAP-1 and survivin mRNA expression patterns were associated with a relatively shorter patient survival, while those of XIAP and livin were associated with a relatively longer patient survival. Abundant protein for all IAPs was also detected in MPM tumours, where they were expressed primarily in the cytoplasm. Only IAP-1 and livin protein was expressed in the nucleus of MPM tumours. These results provide the rationale for additional study of this gene family in MPM and cancer in general. Copyright (c) 2007 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17253596     DOI: 10.1002/path.2121

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  21 in total

Review 1.  Research progress on Livin protein: an inhibitor of apoptosis.

Authors:  Biao Yan
Journal:  Mol Cell Biochem       Date:  2011-05-27       Impact factor: 3.396

2.  BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.

Authors:  Julija Hmeljak; Nina Erčulj; Vita Dolžan; Izidor Kern; Andrej Cör
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-23       Impact factor: 4.553

3.  X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via Rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton.

Authors:  Jinyi Liu; Dongyun Zhang; Wenjing Luo; Yonghui Yu; Jianxiu Yu; Jingxia Li; Xinhai Zhang; Baolin Zhang; Jingyuan Chen; Xue-Ru Wu; Germán Rosas-Acosta; Chuanshu Huang
Journal:  J Biol Chem       Date:  2011-03-14       Impact factor: 5.157

4.  IAP-1 promoted cisplatin resistance in nasopharyngeal carcinoma via inhibition of caspase-3-mediated apoptosis.

Authors:  Xiangwan Miao; Zeyi Deng; Siqi Wang; Huanhuan Weng; Xinting Zhang; Hailiang Li; Huifen Xie; Juan Zhang; Ying Zhong; Bohui Zhang; Quanming Li; Minqiang Xie
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

5.  Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure.

Authors:  Gustav Nilsonne; Eric Olm; Adam Szulkin; Filip Mundt; Agnes Stein; Branka Kocic; Anna-Klara Rundlöf; Aristi P Fernandes; Mikael Björnstedt; Katalin Dobra
Journal:  J Exp Clin Cancer Res       Date:  2009-06-29

6.  Is survivin expression prognostic or predictive in malignant pleural mesothelioma?

Authors:  Julija Hmeljak; Nina Erčulj; Vita Dolžan; Jože Pižem; Izidor Kern; Viljem Kovač; Maja Cemažar; Andrej Cör
Journal:  Virchows Arch       Date:  2013-01-29       Impact factor: 4.064

Review 7.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  Transcriptome sequencing of malignant pleural mesothelioma tumors.

Authors:  David J Sugarbaker; William G Richards; Gavin J Gordon; Lingsheng Dong; Assunta De Rienzo; Gautam Maulik; Jonathan N Glickman; Lucian R Chirieac; Mor-Li Hartman; Bruce E Taillon; Lei Du; Pascal Bouffard; Stephen F Kingsmore; Neil A Miller; Andrew D Farmer; Roderick V Jensen; Steven R Gullans; Raphael Bueno
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-26       Impact factor: 11.205

9.  Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.

Authors:  Larisa L Belyanskaya; Thomas M Marti; Sally Hopkins-Donaldson; Stefanie Kurtz; Emanuela Felley-Bosco; Rolf A Stahel
Journal:  Mol Cancer       Date:  2007-10-22       Impact factor: 27.401

10.  Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.

Authors:  Oluf Dimitri Røe; Adam Szulkin; Endre Anderssen; Arnar Flatberg; Helmut Sandeck; Tore Amundsen; Sten Even Erlandsen; Katalin Dobra; Stein Harald Sundstrøm
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.